Health care stocks leaned lower premarket Thursday with the Health Care Select Sector SPDR Fund (XLV) declining by 0.9% and the iShares Biotechnology ETF (IBB) recently down 1.7%.
Keros Therapeutics (KROS) shares advanced by more than 14% after the company said its board has decided to initiate a formal review process to evaluate strategic alternatives.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.